Prange Pharma recently announced the successful completion of the acquisition of the MSD Animal Health manufacturing site in Aprilia, Italy. Following closing, the site will operate under the new name Aprilia Animal Health, establishing a dedicated European platform for contract manufacturing in the animal health sector.
The transaction marks a key milestone in Prange Pharma’s strategy to expand its footprint in Europe and strengthen its capabilities in animal health manufacturing. With its broad technological setup, including sterile and non-sterile production as well as specialized product categories, Aprilia Animal Health is positioned as a center of excellence for global customers.
At the same time, Prange Pharma and MSD Animal Health are entering a long-term supply partnership, ensuring continuity for existing products and a seamless transition for customers.
With more than 65 years of manufacturing experience and a highly skilled workforce, the Aprilia site will continue to play a critical role in the supply of veterinary pharmaceuticals, while opening new opportunities for third-party CDMO business.
Otto Prange, Owner of Prange Group, commented: “This successful closing represents an important step in executing our long-term growth strategy. Aprilia Animal Health will become a key pillar of our European manufacturing network.”
Sebastian Heckerodt, Managing Director of Prange Pharma, added: “We are proud to officially welcome the Aprilia team to Prange Pharma. Our focus is now on integration, further investment and developing Aprilia Animal Health into a leading CDMO partner for the global animal health industry.”
Angelo Gatto, Co-Shareholder, stated: “Aprilia is a high-standards manufacturing site with broad capabilities and an experienced team. It will be a trusted partner for the animal health industry on global markets.”
Source: chemanager-online.com
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer health business.
Lonza Capsugel is launching UC-Flex, a premium collagen and calcium carbonate blend for pet joint health, at Interzoo 2026. The ingredient is backed by twenty years of research and provides a science-validated dose of collagen to improve mobility in dogs. This product addresses a growing market trend, as global demand for functional pet foods and collagen-based launches continues to rise.
Stryker, a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease.
